virus recombinant containing a DNA copy of an influenza A virus NP gene was constructed. We found that murine cells infected with this virus were efficiently lysed in a major histocompatibility complex-restricted manner by cross-reactive CTL populations obtained by immunization with a variety of influenza A virus subtypes. In addition, the recombinant vaccinia virus containing the PR8 NP gene was able to both stimulate and prime for a vigorous secondary cross-reactive CTL response. Significantly, splenocytes from mice primed by inoculation with the recombinant vaccinia virus containing the PR8 NP gene could be stimulated by influenza A viruses of all three major human subtypes. Finally, unlabeled target competition experiments suggest that NP is a major, but not the sole, viral target antigen recognized by cross-reactive CTL.
Major histocompatibility complex-restricted, virus-specific cytotoxic T lymphocytes (CTL) are a prominent feature of host immune responses to many viruses, where they appear to play a role in limiting viral replication and dissemination (1) (2) (3) . The most intensively studied anti-viral CTL are those specific for influenza A virus-infected cells. Even so, the viral antigens recognized by anti-influenza virus CTL remain largely undefined.
Studies of murine anti-influenza virus CTL identified two general CTL populations, one specific for the immunizing strain and closely related strains within the same subtype ("strain-specific") and the other able to lyse cells infected with any influenza A (but not B) virus ("cross-reactive") (4) (5) (6) . In humans, only cross-reactive CTL have been identified (7, 8) . The two viral glycoproteins, hemagglutinin and neuraminidase, are expressed on infected cell surfaces in large quantities (9) . For this reason, it was thought that they served as the principal target antigens for strain-specific and even cross-reactive CTL, despite the fact that these glycoproteins derived from different subtypes are not serologically cross-reactive (10) . Present evidence suggests, however, that the glycoproteins may represent target antigens for only a minority of both CTL populations (11, 12) . This would mean that CTL predominantly recognize one or a number of the eight nonglycosylated viral structural and nonstructural proteins. The amino acid sequences of these proteins are highly conserved among influenza A viruses, providing a possible explanation for cross-reactive recognition. Although none of them are classical integral membrane proteins, at least the nucleoprotein (NP) (13, 14) , and perhaps several other internal virion proteins (14) (15) (16) (17) (18) (19) , are present on infected cell surfaces, where they could serve as CTL target structures.
To directly examine recognition of influenza A virus proteins by CTL, we have constructed live recombinant vaccinia (Vac) viruses containing DNA copies of influenza virus genes. In a previous report, we showed that a recombinant Vac virus containing an HA gene derived from influenza virus strain Jap [A/Japan/305/57 (H2N2)] (20, 21) is able to prime or stimulate (or both) a secondary anti-Jap CTL response in mice and that cells infected with this recombinant virus are lysed by anti-Jap CTL. It was also found that inoculation of mice with the recombinant virus primed largely for a strain-specific CTL response. In this report, we continue these studies using a recombinant To roughly assess the proportion of NP-specific CTL present in cross-reactive CTL populations, "unlabeled target" competition studies were performed. The lysis of 51Cr-la- Proc. NatL Acad Sci. USA 82 (1985) 8u L Cytotoxicity assays were performed by using BALB/c splenocytes and 5"Cr-labeled virus-infected P815 cells at the effector-totarget ratios indicated.
PR8-infected cells (Fig. 2A) . The specificity of this inhibition is demonstrated by the failure of Vac-or B Lee-infected cells to significantly inhibit lysis. When 51Cr-labeled PR8-infected cells were used as targets for the same CTL, inhibition by NP-Vac-infected cells plateaued at roughly 50o of the killing observed with the control unlabeled target cell inhibitors. In contrast, unlabeled PR8-infected cells were able to almost completely inhibit lysis (Fig. 2B) . The inability of NP-Vacinfected cells to inhibit cross-reactive CTL to a similar extent as cells infected with PR8 or other influenza A viruses was found using other cross-reactive CTL populations as well. These data suggest that a significant portion of crossreactive CTL recognize NP but that other viral antigens may be recognized by cross-reactive CTL as well.
Priming and Stimulation of Cross-Reactive CTL by NP- Vac. To examine the ability of the NP to stimulate crossreactive CTL, splenocytes derived from BALB/c mice previously immunized with NT60 were stimulated in vitro with autologous NP-Vac-infected splenocytes and tested for their ability to lyse P815 cells infected with various influenza viruses. As seen in NP-Vac with autologous NT60-infected splenocytes resulted in the generation of CTL that lysed cells infected with all influenza A viruses tested but not with an influenza B virus (Fig. 4A) . In contrast, similarly stimulated splenocytes from Vac-primed mice produced only background lysis (Fig. 4B ). An additional experiment revealed that inoculation with NPVac resulted in priming for a cross-reactive CTL response upon stimulation with autologous cells infected with any human influenza A subtype virus ( Table 2 ). The specificity of Cytotoxicity assays were performed by using BALB/c splenocytes and 51Cr-labeled virus-infected P815 cells at the effector-totarget ratios indicated.
this recognition is demonstrated by the low levels of specific release given by these CTL on B Lee-infected targets and by the similar low levels given by B Lee-stimulated CTL on influenza A virus-infected targets. These data demonstrate that NP can both prime for and stimulate a vigorous crossreactive CTL response and, along with the data presented above, indicate that NP is a major target antigen for crossreactive CTL. DISCUSSION In a previous communication, we demonstrated the potential of recombinant Vac viruses for studying the specificity of murine anti-influenza virus CTL (21) . We also suggested that, used as live vaccines, these viruses would have the advantage over currently used inactivated or subunit vaccines in priming for secondary CTL responses. In the present study, we have extended this work by placing an influenza virus NP gene into Vac virus and have shown that NP is a major target structure for cross-reactive CTL. This provides direct confirmation of recent reports in which indirect evidence for CTL recognition of NP was presented (24, 25) . It is important to recognize that the present findings do not directly identify the target structure(s) recognized by anti-NP CTL. Thus, it is possible that CTL recognize either native NP, alternative forms of NP produced by cellular processing of the native molecule, or NP-induced alterations in cellular components. At present, the first possibility seems marginally more likely since we have found that anti-NP monoclonal antibodies that lose reactivity upon denaturation of NP bind well to NP expressed on infected cell surfaces (unpublished results). This would suggest that at least some cell surface NP is present in its native form and available as a CTL target structure.
Experiments gauging the effects of NP-Vac inoculation on subsequent murine pulmonary infection with influenza viruses from different subtypes have begun; preliminary results indicate that intravenous injection of NP-Vac primes for a secondary cross-reactive CTL response in lungs of mice subsequently challenged by aerosol infection with HK. Based on present knowledge of CTL function, the priming effect of NP-Vac on a secondary cross-reactive CTL response would be expected to result in reduced viral replication in vaccinated animals (1, 2) . Since the priming effect of influenza virus infection appears to be relatively short-lived (lasting perhaps a few years) (26) , such vaccines may prove useful for certain individuals previously infected with influenza A virus as well as immunologically naive individuals.
This report provides additional evidence for the expression of NP on infected cell surfaces and indicates that its cell surface expression does not require the presence of other influenza virus gene products. The mechanism responsible for NP surface expression is unknown, but previous data suggest it is not due to readsorption of NP leaked or secreted from infected cells (14) . NP is located internally in virions, where it is the major viral protein in the ribonucleoprotein complex. Following infection, it first appears in large quantities in the nucleus and at later times in the cytoplasm as well (9) . In addition to its role as a major viral structural protein, studies with temperature-sensitive mutants suggest it functions in viral RNA transcription and replication (27) . None of these known functions and characteristics suggest a role for cell surface NP in the infectious cycle.
If the expression of NP on cell surfaces is of no functional significance to a productive viral infection, there are two explanations for its occurrence. First, NP may be inadvertently (from the standpoint of both cell and virus) transported to the cell surface, due perhaps to a chance modification of the internal form of the protein. Alternatively, NP may be transported to the cell surface by a deliberate cellular process that functions normally to transport internal cellular proteins to the cell surface. Although the primary purpose of this process may be the renewal and maintenance of cellular machinery, it could also be of value to the organism as a whole in allowing for immune surveillance of internal cellular alterations. A possible example of the functioning of this process is the surface expression of simian virus 40 T antigen, a protein with no known surface function that elicits a vigorous CTL response (28) (29) (30) . In the case of internal oncogene products such as this, or lytic infections with viruses for which expression of viral antigens on the cell surface is not an integral part of the infectious cycle, the existence of such a mechanism would be of obvious benefit. Even in the case of infection with influenza viruses and other viruses whose replication depends on the incorporation of viral proteins into the plasma membrane, the surface expression of internal viral components made early in the infectious cycle could speed immune cytolysis and help limit the amount of infectious progeny produced.
The basis for the cell surface expression of NP must be investigated to determine whether surface NP represents a modified form of the internal protein. Recombinant Vac viruses containing other influenza virus genes can also be used to determine which other nonglycosylated viral proteins are expressed on infected cell surfaces. It is hoped that these studies will help determine the basis for the expression of internal viral proteins on infected cell surfaces. 
